Arcutis Biotherapeutics, Inc. (ARQT) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Westlake Village, CA, United States. The current CEO is Todd Franklin Watanabe.
ARQT has IPO date of 2020-01-31, 342 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $3.11B.
Arcutis Biotherapeutics, Inc. is a biopharmaceutical company headquartered in Westlake Village, California, specializing in the development and commercialization of innovative treatments for dermatological diseases. The company's lead product candidate, ARQ-151, is a topical roflumilast cream that has completed Phase III clinical trials for plaque psoriasis and atopic dermatitis. Arcutis is advancing a robust pipeline that includes ARQ-154 for seborrheic dermatitis and scalp psoriasis, ARQ-252, a selective topical Janus kinase type 1 inhibitor for hand eczema and vitiligo, and ARQ-255, a deeper-penetrating topical formulation designed to treat alopecia areata. The company was incorporated in 2016 and rebranded as Arcutis Biotherapeutics in 2019.
